An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This observational study will assess the median time of treatment duration and the safety of
Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data
will be collected for approximately 24 months.